Investment Q&A

Q: Could you please comment on Prometic's earnings release?
Thank you, Peter

Q: Tst had a great run last week. Do u think it will go further?
Thank u very much

Q: Is CRH cheap relative to its peers? Do you think now is a good time to buy? What is the forward P/E?

Q: Hello,

I am a relatively new member. Love the service. I own a small amount of QHR Corp. I am down about 20%. Your thoughts on this as a long term hold please.

Q: Hello 5i,

Could you please shed some light on PHM's next earnings release and what are the estimates for revenue & EBITDA? Back in August, there were some talks about 3 or 4 outstanding LOIs, do you have any update on the status of these LOIs?

Thank you

Q: Any thoughts on the delay in reporting. Seems like incredibly bad timing.

Slainte, Irishyork

Q: Hello,

We would like to buy a healthcare stock and are considering ENL , CXR and GUD.
Which one would you prefer at this time for a 5 year hold period.

Thank you

Q: Hey Peter & Team,

Trying to get a handle on Merus. I bought a full position @ $1.94 in Jan 2015. Sold 50% at $3.26 in July. Today it is trading @ $1.55.

The street sentiments appear to be fluctuating quite a bit... Early Oct it carried a Strong Buy recommendation from multiple sources with target prices ranging between $3.25 & $4.25. 3 weeks later Mackie & Scotia reduced their targets from $4.25 - $2.70.

Are you able to shed any light on MSL and what we could expect moving forward?

Thanks for all you do

Gord

Q: PHM continues to hit new lows. Is it time to double down, stay the course or to cut losses? I took a position earlier this year for the speculative part of my portfolio.

Q: Thoughts on CXR's Q3 and guidance?

http://finance.yahoo.com/news/concordia-healthcare-announces-third-quarter-220000345.html

Q: Hi Peter & team,
I have nothing in healthcare and would like to initiate a 5% position in my RRIF. Is XCR too risky for the moment? How about GUD? Maybe 2.5% in each? Thanks

Q: Please comment what do you think the market reaction would be to their announcement of delay in financials and preliminary results. Thanks

Q: Hey Peter & Team,

Caveat... It's a US company so I appreciate if you are not prepared to answer but considering the Canadian market right now, the US is where we need to be until O&G starts to return to it's old self.

In Feb 2014 I inquired about MCK and you replied with;

"solid blue chip company in the health care space. At 20 times' earnings it is not cheap (after a 70% one year gain) but we note a strong balance sheet, good revenue growth and solid earnings growth."

At the time it was at $176.50. May of this year it peaked at $240.61. As of today with the healthcare sector getting hit in the last 6 months it's around $182.00 which is the lowest it has been since May 2014.

It has a reasonable and very sustainable dividend. Guidance continues to be excellent on both the top and bottom, and they just announced a $2BB share buy-back program.

It appears to me this equity is considerably cheaper than it was back in Feb 2014 when it was $170/sh, and I am having a tough time finding reasons why we shouldn't expect this stock to bounce back over the $200 mark in the very near future.

Am I missing anything? Not aware of something? What is your opinion of its recent report and do you still consider it as expensive as it was in Feb 2014? Finally, do you think I should buy or hold?

Yours Truly

Gun Shy Gord

ps... thanks for all you do

Q: In my RRSP Account, my Patient Home Monitoring position is down 60%, I'm considering selling it and adding to my 2.5 weighting in Concordia which I purchased this week. If I proceed, I'd have a 4% weight in CXR. I'd appreciate 5i's opinion to make the switch or hold PHM or a few more quarters?

Q: Can you comment on the recent earnings release? Also what do you think of the company going forward?

Q: No questions on this one since Feb 2014. I note your concerns expressed at that time. While still not much in the way of financial results, I cannot help but wonder why Clive Beddoe would assume the role of chairman of the board (April 2015). I also note Wilmot Mathews, also on the board of WestJet, is a board member. You wouldn't think that these guys would get involved with a 25m market cap company unless they saw something in it. Your thoughts would be appreciated.

Q: Greetings: I still hold ENL from back in the Paladin days. It and Knight (GUD) make up about 3% each of my portfolio. Endo's quarterly statement seemed fairly positive to me, but the stock dropped significantly. Is it in the same boat as Concordia and Valeant. In other words, should I continue to hold it, or is there some problem. If you say it is similar to Concordia, I will probably just keep it. Thanks, as always, for valued opinion.

Q: PLI has had some positive news lately and stock seems to be responding well. Do you think the news supports the current value and would you recommend it as a buy at current levels.
Thanks
John

Q: Before I logged into my account I was reading an article by Ryan about Concordia and half way through it, it said to read the rest or to read articles like this join 5i Research. I am a member so where would I find the rest of this article? I have a 200 shares at higher prices and I was thinking of averaging down to buy at between $38 and $40. Is that a good idea and where would I find the rest of this article on CXR? Thanks for keeping us posted on this situation. Dennis

Q: Just a comment as it appears some folks are still buying. How does this Enron style Co. justify financial statements listing
over 17B in Goodwill & Net Intangibles over 22B! Why, this puts them in the same value class as Johnson & Johnson. REALLY!